Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12955/2110
Título : Nanoformulations with Leishmania braziliensis antigens triggered controlled parasite burden in vaccinated golden hamster (Mesocricetus auratus) against visceral Leishmaniasis
Autor : Ottino, Jennifer
Leite, Jaqueline Costa
Melo-Júnior, Otoni Alves
Cabrera González, Marco Antonio
de Carvalho, Tatiane Furtado
Garcia, Giani Martins
Batista, Maurício Azevedo
Silveira, Patrícia
Cardoso, Mariana Santos
Bueno, Lilian Lacerda
Fujiwara, Ricardo Toshio
Santos, Renato Lima
Paes, Paulo Ricardo de Oliveira
Silveira-Lemos, Denise
Martins-Filho, Olindo Assis
Galdino, Alexsandro Sobreira
Chávez-Fumagalli, Miguel Angel
Dutra, Walderez Ornelas
Mosqueira, Vanessa Carla Furtado
Giunchetti, Rodolfo Cordeiro
Fecha de publicación : 31-oct-2022
Publicado en: Vaccines
Resumen : Leishmaniasis is a widespread vector-borne disease in Brazil, with Leishmania (Leishmania) infantum as the primary etiological agent of visceral leishmaniasis (VL). Dogs are considered the main reservoir of this parasite, whose treatment in Brazil is restricted to the use of veterinary medicines, which do not promote a parasitological cure. Therefore, efficient vaccine development is the best approach to Canine Visceral Leishmaniasis (CVL) control. With this in mind, this study used hamsters (Mesocricetus auratus) as an experimental model in an anti-Leishmania preclinical vaccine trial to evaluate the safety, antigenicity, humoral response, and effects on tissue parasite load. Two novel formulations of nanoparticles made from poly(D, L-lactic) acid (PLA) polymer loading Leishmania braziliensis crude antigen (LB) exhibiting two different particle sizes were utilized: LBPSmG (570 nm) and LBPSmP (388 nm). The results showed that the nanoparticles were safe and harmless to hamsters and were antigenic with the induction in LBSap, LBPSmG, and LBPSmG groups of total anti-Leishmania IgG antibodies 30 days after challenge, which persists 200 days in LBSap and LBPSmP. At the same time, a less pronounced hepatosplenomegaly in LBSap, LBPSmG, and LBPSmP was found when compared to control groups, as well as a less pronounced inflammatory infiltrate and granuloma formation in the spleen. Furthermore, significant reductions of 84%, 81%, and 90% were observed in spleen parasite burden accessed by qPCR in the LBSap, LBPSmG, and LBPSmP groups, respectively. In this way, LBSap, LBPSmG, and LBPSmP formulations showed better results in vaccinated and L. infantum-challenged animals in further reducing parasitic load in the spleen and attenuating lesions in liver and splenic tissues. This results in safe, harmless nanoformulation vaccines with significant immunogenic and infection control potential. In addition, animals vaccinated with LBPSmP had an overall reduction in parasite burden in the spleen, indicating that a smaller nanoparticle could be more efficient in targeting antigen-presenting cells.
Palabras clave : Visceral leishmaniasis
Polymeric nanoparticle
Pre-clinical trial
metadata.dc.subject.agrovoc: Leishmaniasis
Mesocricetus auratus
Editorial : MDPI
Citación : Ottino, J., Leite, J. C., Melo-Júnior, O. A., González, M. A. C., de Carvalho, T. F., Garcia, G. M., Batista, M. A., Silveira, P., Cardoso, M. S., Bueno, L. L., Fujiwara, R. T., Santos, R. L., Paes, P. R. de O., Silveira-Lemos, D., Martins-Filho, O. A., Galdino, A. S., Chávez-Fumagalli, M. A., Dutra, W. O., Mosqueira, V. C. F., & Giunchetti, R. C. (2022). Nanoformulations with Leishmania braziliensis antigens triggered controlled parasite burden in vaccinated golden hamster (Mesocricetus auratus) against visceral Leishmaniasis. Vaccines, 10(11), 1848. doi: 10.3390/vaccines10111848
URI : https://hdl.handle.net/20.500.12955/2110
metadata.dc.identifier.doi: https://doi.org/10.3390/vaccines10111848
ISSN : 2076-393X
metadata.dc.subject.ocde: https://purl.org/pe-repo/ocde/ford#1.06.01
Aparece en las colecciones: Artículos científicos

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Ottino_et-al_2022_visceral_leishmaniasis.pdfArtículo3,91 MBAdobe PDFVisualizar/Abrir

Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons